BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
October 25 2019 - 1:00AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the
development of innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, today announced that it
will be presenting at the Dawson James Securities 5th Annual Small
Cap Growth Conference, being held on October 28-29, 2019 at the
Wyndham Grand Hotel in Jupiter, Florida.
Preetam Shah, PhD, MBA, Chief Financial Officer
is scheduled to present on Tuesday, October 29th at 3:40 p.m.
Eastern Time, in Track 2 - Preserve Ballroom B, with one-on-one
meetings to be held throughout the conference.
Chaim Lebovits, President and CEO of BrainStorm
said, “We are pleased to have the opportunity to have Dr. Shah
present at the Dawson James Small Cap Growth Conference. Dr. Shah,
joined BrainStorm in September 2019, and we look forward to having
him present the Company’s growth strategy and future to a wide
audience of accreditied investors.”
About NurOwn® NurOwn® (autologous MSC-NTF cells) represent a
promising investigational approach to targeting disease pathways
important in neurodegenerative disorders. MSC-NTF cells are
produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. NurOwn® is
currently being evaluated in a Phase 3 ALS randomized
placebo-controlled trial and in a Phase 2 open-label multicenter
trial in Progressive MS.
About BrainStorm Cell Therapeutics
Inc. BrainStorm Cell Therapeutics Inc. is a
leading developer of innovative autologous adult stem cell
therapeutics for debilitating neurodegenerative diseases. The
Company holds the rights to clinical development and
commercialization of the NurOwn® Cellular Therapeutic Technology
Platform used to produce autologous MSC-NTF cells through an
exclusive, worldwide licensing agreement. Autologous MSC-NTF cells
have received Orphan Drug status designation from the U.S. Food and
Drug Administration (U.S. FDA) and the European Medicines Agency
(EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal
trial in ALS (NCT03280056), investigating repeat-administration of
autologous MSC-NTF cells at six sites in the U.S., supported by a
grant from the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a BLA filing
for U.S. FDA approval of autologous MSC-NTF cells in ALS.
BrainStorm received U.S. FDA clearance to initiate a Phase 2
open-label multi-center trial of repeat intrathecal dosing of
MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in
December 2018 and has been enrolling clinical trial participants
since March 2019. For more information, visit the company's
website.
Safe-Harbor
Statements
Statements in this announcement other than historical data
and information, including statements regarding future clinical
trial enrollment and data, constitute "forward-looking statements"
and involve risks and uncertainties that could
cause BrainStorm Cell Therapeutics Inc.'s actual results
to differ materially from those stated or implied by such
forward-looking statements. Terms and phrases such as "may",
"should", "would", "could", "will", "expect", "likely", "believe",
"plan", "estimate", "predict", "potential", and similar terms and
phrases are intended to identify these forward-looking statements.
The potential risks and uncertainties include, without limitation,
BrainStorm’s need to raise additional capital, BrainStorm’s ability
to continue as a going concern, regulatory approval of BrainStorm’s
NurOwn® treatment candidate, the success of BrainStorm’s product
development programs and research, regulatory and personnel issues,
development of a global market for our services, the ability to
secure and maintain research institutions to conduct our clinical
trials, the ability to generate significant revenue, the ability of
BrainStorm’s NurOwn® treatment candidate to achieve broad
acceptance as a treatment option for ALS or other neurodegenerative
diseases, BrainStorm’s ability to manufacture and commercialize the
NurOwn® treatment candidate, obtaining patents that provide
meaningful protection, competition and market developments,
BrainStorm’s ability to protect our intellectual property from
infringement by third parties, heath reform legislation, demand for
our services, currency exchange rates and product liability claims
and litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTS
Corporate: Uri Yablonka Chief
Business Officer BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188 uri@brainstorm-cell.com
Media:Sean LeousWestwicke/ICR PR Phone:
+1.646.677.1839sean.leous@icrinc.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2023 to Apr 2024